JP2020505948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505948A5 JP2020505948A5 JP2019559395A JP2019559395A JP2020505948A5 JP 2020505948 A5 JP2020505948 A5 JP 2020505948A5 JP 2019559395 A JP2019559395 A JP 2019559395A JP 2019559395 A JP2019559395 A JP 2019559395A JP 2020505948 A5 JP2020505948 A5 JP 2020505948A5
- Authority
- JP
- Japan
- Prior art keywords
- asp
- ser
- lys
- cys
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000019298 Lipocalin Human genes 0.000 claims description 68
- 108050006654 Lipocalin Proteins 0.000 claims description 68
- 102000017578 LAG3 Human genes 0.000 claims description 25
- 101150030213 Lag3 gene Proteins 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 14
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 230000032823 cell division Effects 0.000 claims description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 108020001580 protein domains Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17151945.7 | 2017-01-18 | ||
| EP17151945 | 2017-01-18 | ||
| PCT/EP2018/051139 WO2018134274A1 (en) | 2017-01-18 | 2018-01-18 | Lipocalin muteins with binding affinity for lag-3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505948A JP2020505948A (ja) | 2020-02-27 |
| JP2020505948A5 true JP2020505948A5 (OSRAM) | 2021-02-25 |
| JP7225116B2 JP7225116B2 (ja) | 2023-02-20 |
Family
ID=57860697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559395A Active JP7225116B2 (ja) | 2017-01-18 | 2018-01-18 | Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11168119B2 (OSRAM) |
| EP (1) | EP3571219A1 (OSRAM) |
| JP (1) | JP7225116B2 (OSRAM) |
| KR (1) | KR20190104409A (OSRAM) |
| CN (1) | CN110402252A (OSRAM) |
| AU (1) | AU2018209178B2 (OSRAM) |
| BR (1) | BR112019014691A2 (OSRAM) |
| CA (1) | CA3050194A1 (OSRAM) |
| MX (1) | MX2019008434A (OSRAM) |
| RU (1) | RU2019122482A (OSRAM) |
| SG (1) | SG11201906509WA (OSRAM) |
| WO (1) | WO2018134274A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016293101B2 (en) | 2015-07-15 | 2022-06-16 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for LAG-3 |
| JP7225116B2 (ja) | 2017-01-18 | 2023-02-20 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| WO2021245240A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| JP2024515564A (ja) * | 2021-04-08 | 2024-04-10 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 結合組織増殖因子（ｃｔｇｆ）に特異的な新規リポカリンムテイン |
| CN113480667B (zh) * | 2021-08-17 | 2023-03-28 | 长春萤火虫生物科技有限公司 | 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用 |
| CN113754743B (zh) * | 2021-10-12 | 2024-02-02 | 成都齐碳科技有限公司 | 孔蛋白单体的突变体、蛋白孔及其应用 |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| NZ508249A (en) | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| AU4505399A (en) | 1999-06-02 | 2000-12-28 | Abb Research Ltd | Coating composition for high temperature protection |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2517287C (en) | 2003-02-28 | 2022-12-13 | The Johns Hopkins University | Regulation of t cells by lag-3 (cd223) |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| WO2007107563A2 (en) * | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| RU2515063C9 (ru) | 2008-01-30 | 2014-08-10 | Пиерис АГ | Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека, и способы их получения |
| CN109432402B (zh) | 2011-12-13 | 2022-04-29 | 皮里斯制药有限公司 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
| WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP3441400B1 (en) * | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CA2980838A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| AU2016293101B2 (en) | 2015-07-15 | 2022-06-16 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for LAG-3 |
| JP7225116B2 (ja) | 2017-01-18 | 2023-02-20 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン |
-
2018
- 2018-01-18 JP JP2019559395A patent/JP7225116B2/ja active Active
- 2018-01-18 EP EP18702146.4A patent/EP3571219A1/en not_active Withdrawn
- 2018-01-18 WO PCT/EP2018/051139 patent/WO2018134274A1/en not_active Ceased
- 2018-01-18 RU RU2019122482A patent/RU2019122482A/ru not_active Application Discontinuation
- 2018-01-18 BR BR112019014691A patent/BR112019014691A2/pt not_active IP Right Cessation
- 2018-01-18 MX MX2019008434A patent/MX2019008434A/es unknown
- 2018-01-18 AU AU2018209178A patent/AU2018209178B2/en not_active Ceased
- 2018-01-18 CN CN201880017771.8A patent/CN110402252A/zh active Pending
- 2018-01-18 SG SG11201906509WA patent/SG11201906509WA/en unknown
- 2018-01-18 US US16/478,465 patent/US11168119B2/en not_active Expired - Fee Related
- 2018-01-18 CA CA3050194A patent/CA3050194A1/en active Pending
- 2018-01-18 KR KR1020197023946A patent/KR20190104409A/ko not_active Ceased
-
2021
- 2021-10-12 US US17/499,640 patent/US11773147B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505948A5 (OSRAM) | ||
| JP2018532372A5 (OSRAM) | ||
| JP2018515084A5 (OSRAM) | ||
| Tai et al. | A bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino-terminal to antidigoxin single-chain Fv | |
| Glockshuber et al. | A comparison of strategies to stabilize immunoglobulin Fv-fragments | |
| JP2018519802A5 (OSRAM) | ||
| Uthaipibull et al. | Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum | |
| JP2014502149A5 (OSRAM) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| JP2017518748A5 (OSRAM) | ||
| JP3474574B2 (ja) | 結合特異性を有する組換ジスルフィド安定化ポリペプチドフラグメント | |
| Yamamoto et al. | Purification and characterization of a GTP-binding protein with a molecular weight of 20,000 in bovine brain membranes. Identification as the rho gene product. | |
| JP2019506140A5 (OSRAM) | ||
| JP2002542157A5 (OSRAM) | ||
| JP2018526989A5 (OSRAM) | ||
| JPH06510902A (ja) | Ｒｆｋｂｐ：新規なプロリルイソメラーゼおよびラパマイシン／ｆｋ５０６結合タンパク質 | |
| JP2020530285A5 (OSRAM) | ||
| JP2017515457A (ja) | ＴＮＦαに対する結合メンバー | |
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| JP2018509887A5 (OSRAM) | ||
| JP2013512683A5 (OSRAM) | ||
| EA012507B1 (ru) | Высокоаффинные мелан-а т-клеточные рецепторы | |
| EP2274336A2 (en) | Mutants of streptokinase and their covalently modified forms | |
| CA2332570A1 (en) | Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine |